Mabs - Bioprocess Development Forum

Articles Regulatory

August 8, 2024

Since the FDA approved the first monoclonal based therapy in 1985, mAbs have had significant…

Ross Burns

Articles Downstream

May 30, 2024

Significant operational improvements can be achieved by intensified continuous processes compared to standard batch processes.

Ross Burns

Articles

September 21, 2023

The growth in the formulation of drugs suitable for delivery by subcutaneous (Sub-C) injection...

admin-element

Articles Downstream

June 13, 2023

Continued development of new and next-generation antibodies is spurred by the increasing demand for more…

admin-element

Articles BioPharma Downstream Upstream

November 4, 2021

The 2000-L-scale SUB has been the mainstay of large-scale SUBs since its introduction. Yasser...

admin-element

Articles Downstream Upstream

September 9, 2021

Antibody-based therapies have evolved beyond monoclonal antibodies (mAbs) to include bispecific...

admin-element

Articles BioPharma Downstream Upstream

January 31, 2019

Ensuring the stability of biotherapeutic products, which has an impact on their safety and...

admin-element

Articles

March 30, 2016

The Chinese hamster ovary (CHO) cell lines used for the production of recombinant therapeutic proteins...

admin-element

Articles BioPharma Upstream

February 18, 2016

The biopharmaceutical industry is growing exponentially, driven by an ever-increasing demand for monoclonal antibodies (mAbs)…

admin-element